Coultreon Biopharma
Biotech · Healthcare
Coultreon Biopharma Secures $125M Series A for SIK3 Inhibitor
April 28, 2026$125M · Series A
Coultreon Biopharma closed an oversubscribed $125 million Series A to advance its lead oral SIK3 inhibitor COL-5671 into Phase 2 trials for psoriasis and ulcerative colitis. The round was led by Sofinnova Investments with Forbion and Novo Holdings as co-leads.
Lead Investors
Sofinnova InvestmentsForbionNovo Holdings
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.